Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03492762 · ClinicalTrials.gov registry record · Early Phase 1
PET Imaging CCR2 in Lung Inflammation
A Early Phase 1 study of Lung Inflammation, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT03492762 is a Early Phase 1 study of Lung Inflammation that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 110 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03492762, a Early Phase 1 study of Lung Inflammation, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to assess the lung distribution of the Positron Emission Tomography (PET) imaging radiotracer Cu-DOTA-ECL1i, which binds to the specific population inflammatory cells, in patients with fibrotic lung diseases. This objective includes sub-studies to assess radiotracer distribution in the lung, the reproducibility of PET scans and the relationship of the scan to distribution of inflammatory cells in human lung tissue. The overall goal is to assess the potential of the radiotracer to track inflammatory cells in lung diseases.
Conditions Studied
Interventions
- DRUG Cu-DOTA-ECL1i
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2026-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03492762
The ClinicalTrials.gov registry entry for NCT03492762 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Inflammation appearing as the primary indexed condition, and to 1 intervention - of which Cu-DOTA-ECL1i is the first listed.
NCT03492762 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT03492762 about?
NCT03492762 is a clinical study titled "PET Imaging CCR2 in Lung Inflammation". The primary objective of this study is to assess the lung distribution of the Positron Emission Tomography (PET) imaging radiotracer Cu-DOTA-ECL1i, which binds to the specific population inflammatory cells, in patients with fibrotic lung diseases. This objective includes sub-studies to assess radiot...
What is the current status of trial NCT03492762?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 110 participants. The study started on 2018-02-27. Estimated completion is 2026-12-31.
What conditions does trial NCT03492762 study?
This clinical trial studies the following conditions: Lung Inflammation.
What interventions are being tested in trial NCT03492762?
The interventions under investigation include: Cu-DOTA-ECL1i (DRUG).
Who is sponsoring clinical trial NCT03492762?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03492762 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.